GLP1-RA and Periodontitis

Medical University of Graz

Status: Not yet enrolling

Conditions: Diabetes (DM); Periodontitis

Study type: Observational

Funder types: Other

Identifiers

NCT07182123

1378/2025

Details and patient eligibility

About

Periodontitis is among the most common chronic diseases worldwide and, along with caries, represents the leading cause of tooth loss. More recent theories regarding the etiology of periodontitis also attribute a significant role to the body's inflammatory response in the development and progression of the disease.

It is already well established that periodontitis is bidirectionally associated with other systemic inflammatory conditions, such as type 2 diabetes mellitus. Results from meta-analyses suggest that diabetes increases the likelihood of periodontal disease by approximately 24%, while periodontitis, conversely, raises the risk of type 2 diabetes by about 26%.

In addition to primary preventive measures and the modification of modifiable risk factors, diabetes mellitus is also treated pharmacologically with GLP-1 receptor agonists (GLP-1RA). In this context, Zhang et al. demonstrated that the administration of GLP-1RA, both in vitro and in vivo in rat models, leads to a significant reduction of pro-inflammatory substances in blood and periodontal tissue. However, to date, no clinical studies have investigated the effect of GLP-1RA on periodontal disease in humans.

For this reason, the aim of this pilot study is to investigate the effect of GLP-1RA on the periodontal status of patients with periodontitis. The data from this pilot study will subsequently be used to perform a power analysis to determine the sample size for a double-blind, placebo-controlled clinical trial.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent for participation and data protection
• Diagnosis of type 2 diabetes
• Diagnosis of chronic periodontitis (Caton, Armitage et al. 2018), presence of a PSI ≥ 3 in at least one sextant (Ainamo, Barmes et al. 1982)

Exclusion criteria

• Use of systemic antibiotics within the past 6 months
• Systematic periodontal treatment within the past 24 months
• Consumption of ≥ 5 cigarettes/day
• Unstable cardiovascular disease
• Chronic systemic diseases (e.g., rheumatoid arthritis, Crohn's disease, etc.)
• Pregnancy
• Use of the following medications: Immunosuppressants, Anticonvulsants, Calcium channel blockers
• Drug or medication abuse